IPO · Healthcare & Life Sciences

Molbio Diagnostics lists at 21% premium on exchanges

By Startup Enthusiast · 17 August 2026

What they do

Molbio Diagnostics makes point-of-care molecular diagnostic systems for multiple diseases

Its Rs 939.7 crore IPO listed at Rs 980, a 21.44% premium over the issue price of Rs 807

The IPO was subscribed 70.27 times, and the company's market cap at listing was Rs 11,628 crore

Molbio Diagnostics shares listed on NSE and BSE at Rs 980, a 21.44% premium over the IPO price of Rs 807.
The IPO size was Rs 939.7 crore, comprising a fresh issue of Rs 200 crore and an offer for sale of Rs 739.7 crore.
The IPO price band was Rs 768-807 per share, with a lot size of 18 shares and a retail minimum investment of Rs 14,526.
The IPO was subscribed 70.27 times.
At listing, the company's market capitalisation was Rs 11,628 crore ($1.22 billion).
By 10:51 AM on listing day, the share price had risen to Rs 1008.40.
Before listing, the grey market premium was around Rs 120, indicating an expected price of about Rs 927.

The strong listing reflects high investor demand for diagnostics companies in India.
Molbio's Truenat platform gained prominence during the COVID-19 pandemic for its portable testing capability.
Bill Gates has publicly praised Molbio's role in increasing diagnostic tests and affordability in India.

Molbio Diagnostics is known for its Truenat platform, a point-of-care molecular diagnostics system for multiple diseases.
The company places diagnostic devices at healthcare facilities and earns recurring revenue from test kit sales.
As per IPO documents, the Truenat platform had 30 diseases and 42 assays commercialised.
Its wholly owned subsidiary Bigtec Labs handles R&D for diagnostic platforms at point-of-care settings.
The company has a global footprint with installations in Asia/Oceania, Africa/Middle East, Europe/Central Asia, and the Americas.
Molbio's technology has touched 40+ million lives across 90+ countries (the website also mentions 80+ countries).
Molbio's EDGE is a global accelerator programme for point-of-need diagnostic technologies.